Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Surgeon-Authored Virtual Laparoscopic Adrenalectomy Module Is Judged Effective and Preferred Over Traditional Teaching Tools.

Kurenov S, Cendan J, Dindar S, Attwood K, Hassett J, Nawotniak R, Cherr G, Cance WG, Peters J.

Surg Innov. 2017 Feb;24(1):72-81. doi: 10.1177/1553350616672971.

PMID:
27758896
2.

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.

Marlowe TA, Lenzo FL, Figel SA, Grapes AT, Cance WG.

Mol Cancer Ther. 2016 Dec;15(12):3028-3039.

PMID:
27638858
3.

Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.

Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK.

Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190.

PMID:
27336608
4.

Synthesis and bioactivity of a Goralatide analog with antileukemic activity.

Li Z, Lebedyeva IO, Golubovskaya VM, Cance WG, Alamry KA, Faidallah HM, Dennis Hall C, Katritzky AR.

Bioorg Med Chem. 2015 Aug 1;23(15):5056-60. doi: 10.1016/j.bmc.2015.04.061.

PMID:
26048023
5.

Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Golubovskaya V, O'Brien S, Ho B, Heffler M, Conroy J, Hu Q, Wang D, Liu S, Cance WG.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1613-31. doi: 10.1007/s00432-015-1924-3.

PMID:
25656374
6.

A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG.

Cell Cycle. 2014;13(16):2542-53. doi: 10.4161/15384101.2015.941760.

7.

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs.

Wilton J, Kurenova E, Pitzonka L, Gaudy A, Curtin L, Sexton S, Cance W, Fetterly G.

Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):55-67. doi: 10.1007/s13318-014-0233-6.

8.

High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.

Golubovskaya VM, Ylagan L, Miller A, Hughes M, Wilson J, Wang D, Brese E, Bshara W, Edge S, Morrison C, Cance WG.

BMC Cancer. 2014 Oct 17;14:769. doi: 10.1186/1471-2407-14-769.

9.
10.

Low dose four-dimensional computerized tomography with volume rendering reconstruction for primary hyperparathyroidism: How I do it?

Platz TA, Kukar M, Elmarzouky R, Cance W, Abdelhalim A.

World J Radiol. 2014 Sep 28;6(9):726-9. doi: 10.4329/wjr.v6.i9.726. Review.

11.
12.

The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.

Dy GK, Ylagan L, Pokharel S, Miller A, Brese E, Bshara W, Morrison C, Cance WG, Golubovskaya VM.

J Thorac Oncol. 2014 Sep;9(9):1278-84. doi: 10.1097/JTO.0000000000000248.

13.

The use of modified four-dimensional computed tomography in patients with primary hyperparathyroidism: an argument for the abandonment of routine sestamibi single-positron emission computed tomography (SPECT).

Kukar M, Platz TA, Schaffner TJ, Elmarzouky R, Groman A, Kumar S, Abdelhalim A, Cance WG.

Ann Surg Oncol. 2015 Jan;22(1):139-45. doi: 10.1245/s10434-014-3940-y.

PMID:
25074663
14.

Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.

Gogate PN, Kurenova EV, Ethirajan M, Liao J, Yemma M, Sen A, Pandey RK, Cance WG.

Cancer Lett. 2014 Oct 28;353(2):281-9. doi: 10.1016/j.canlet.2014.07.032.

15.

In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).

Golubovskaya V, Curtin L, Groman A, Sexton S, Cance WG.

Arch Toxicol. 2015 Jul;89(7):1095-101. doi: 10.1007/s00204-014-1290-y.

PMID:
24915938
16.

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.

Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG.

Eur J Med Chem. 2014 Jun 10;80:154-66. doi: 10.1016/j.ejmech.2014.04.041.

17.

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.

Golubovskaya VM, Ho B, Conroy J, Liu S, Wang D, Cance WG.

Cancers (Basel). 2014 Jan 21;6(1):166-78. doi: 10.3390/cancers6010166.

18.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

Kurenova E, Liao J, He DH, Hunt D, Yemma M, Bshara W, Seshadri M, Cance WG.

Oncotarget. 2013 Oct;4(10):1632-46.

19.

Translational cancer research for surgeons.

Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):xv-xvi. doi: 10.1016/j.soc.2013.06.013. No abstract available.

PMID:
24012406
20.

Targeting the p53 pathway.

Golubovskaya VM, Cance WG.

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Review.

Items per page

Supplemental Content

Loading ...
Support Center